Jiawei Zheng | Toxicology | Excellence in Research Award

Mr. Jiawei Zheng | Toxicology | Excellence in Research Award 

Jinquan Satellite Launch Center Hospital | China

Jiawei Zheng is an attending doctor at the Jiuquan Satellite Launch Center Hospital whose work integrates clinical practice with specialized research in occupational toxicology, particularly focusing on hepatotoxicity mechanisms relevant to aerospace environments. Trained in medical sciences with a concentration in toxicology, he has built a career that blends laboratory investigation with applied aerospace-medicine service, serving as a principal investigator for internally supported projects aimed at understanding and mitigating toxin-induced organ injury. His research explores oxidative stress, apoptosis signaling, and metabolic intervention, with special emphasis on the pathways disrupted by exposure to aerospace-related chemicals. He has developed strong skills in experimental design, animal modeling, cellular and biochemical analysis, mechanistic interpretation, and scientific writing, demonstrated through his first-author contribution to a peer-reviewed article that reveals a novel mechanistic pathway underlying UDMH-induced liver injury. His professional experience also includes leading a hospital consultancy initiative focused on toxicological risk assessment. Although early in his publication journey, his work has already contributed meaningful insights to the field of hepatotoxicity research. With dedication to advancing occupational health protection for aerospace personnel, he continues to pursue research that supports scientific innovation, clinical safety, and the broader mission of improving health resilience in high-risk technological environments.

Profile: ORCID

Featured Publications

Zheng, J., Liu, W., Zhu, X., Ran, L., Lang, H., Yi, L., Mi, M., & Zhu, J. (2020). Pterostilbene enhances endurance capacity via promoting skeletal muscle adaptations to exercise training in rats. Molecules, 25(1), 186.

Huang, Y., Zhu, X., Chen, K., Lang, H., Zhang, Y., Hou, P., Ran, L., Zhou, M., Zheng, J., Yi, L., & Mi, M. (2019). Resveratrol prevents sarcopenic obesity by reversing mitochondrial dysfunction and oxidative stress via the PKA/LKB1/AMPK pathway. Aging (Albany NY), 11(8), 2217–2240.

 

Elif Baris | Pharmacology | Excellence in Research Award

Assoc. Prof. Dr. Elif Baris | Pharmacology | Excellence in Research Award

İzmir University of Economics | Turkey

Elif Baris is an Assistant Professor of Medical Pharmacology at Izmir University of Economics, specializing in molecular pharmacology with a strong focus on inflammation, pain physiology, and cholinergic anti-inflammatory mechanisms. She holds a pharmacy degree and a doctoral qualification in medical pharmacology from Dokuz Eylül University, and has developed expertise in cytokine signaling, oxidative stress, neuroimmune modulation, molecular oncology, stem cell immunoregulation, and sepsis models. Her professional experience includes leading and contributing to numerous multidisciplinary research projects supported by national and institutional scientific bodies, alongside collaborations with prominent medical and biotechnology institutions. Her research interests extend to autonomic nervous system pharmacology, neuroimmune interactions, mechanotransduction through TRPV4 channels, and innovative drug repurposing strategies. She possesses strong research skills in qRT-PCR, Western blotting, ELISA, cytokine arrays, flow cytometry, and real-time cell analysis, supported by extensive publications in indexed journals and multiple patents involving varenicline- and choline-based therapeutic applications. She has received recognition through collaborative roles in funded research, chapter authorship in academic publications, and contributions to translational pharmacology. Her professional memberships include national societies in pharmacology and physiology, reflecting her commitment to scientific advancement. With her growing contributions to drug innovation, inflammation therapeutics, and molecular pharmacology, she continues to advance impactful research aimed at improving mechanisms of pain management and immune regulation.

Profile: Google scholar

Featured Publications

Baris, E., Efe, H., Gumustekin, M., Arici, M. A., & Tosun, M. (2021). Varenicline prevents LPS-induced inflammatory response via nicotinic acetylcholine receptors in RAW 264.7 macrophages. Frontiers in Molecular Biosciences, 8, 721533. [15 citations]

Baris, E., Simsek, O., Arici, M. A., & Tosun, M. (2023). Choline and citicoline ameliorate oxidative stress in acute kidney injury in rats. Bratislava Medical Journal / Bratislavské Lekárske Listy, 124(1). [12 citations]

Baris, E., Simsek, O., Efe, H., Oncu, S., Gelal, A., Hamurtekin, E., Tosun, M., … (2021). Effects of CDP-choline and choline on COX pathway in LPS-induced inflammatory response in rats. International Journal of Pharmacology, 17(2), 84–96. [10 citations]

Baris, E., Arici, M. A., & Tosun, M. (2024). Nicotinic acetylcholine receptor-mediated effects of varenicline on LPS-elevated prostaglandin and cyclooxygenase levels in RAW 264.7 macrophages. Frontiers in Molecular Biosciences, 11, 1392689. [4 citations]

 

Ronald Castelino | Nephrology | Best Researcher Award

Assoc. Prof. Dr. Ronald Castelino | Nephrology | Best Researcher Award

Head of Pharmacy Practice, University of Sydney, Australia

Ronald L. Castelino, BPharm, MPharm, PhD, PDCR, MSHPA, is an Associate Professor in Pharmacology & Clinical Pharmacy at the University of Sydney and an Adjunct Senior Lecturer at the University of Tasmania. With a strong academic foundation and global experience in clinical pharmacy, especially nephrology, he focuses on the quality use of medicines in chronic diseases. His academic journey spans India and Australia, backed by leadership in teaching and translational research. He contributes extensively to nursing and pharmacy education while holding an active pharmacist role at Blacktown Hospital. Dr. Castelino has co-supervised multiple postgraduate research projects, published over 90 papers, and leads a research group focused on kidney disease management and medication safety. He is Board Certified in Geriatric Pharmacy and a Fellow of the Australia and New Zealand College of Advanced Pharmacy. A passionate educator, clinician, and researcher, he embodies a multidisciplinary approach to advancing pharmacy practice and patient-centered care.

Profile

🎓 Education

Dr. Ronald Castelino holds a PhD in Pharmacy Practice from the University of Sydney (2011), an MPharm in Pharmacy Practice (2006), and a BPharm (2003) from Rajiv Gandhi University of Health Sciences, Bangalore, India. He also completed a Professional Diploma in Clinical Research (PDCR, 2006) and is Board Certified in Geriatric Pharmacy (BCGP, 2018). In 2024, he was honored as a Fellow of the Australia and New Zealand College of Advanced Pharmacy (FANZCAP) for his contributions to nephrology and research. His educational achievements are distinguished with high academic honors, including a Gold Medal and Second Rank in his MPharm degree. This diverse educational background underpins his extensive work in clinical pharmacology, research methodology, and teaching. His academic preparation reflects a balance of clinical training, research competence, and leadership in the pharmaceutical sciences. These qualifications have enabled him to impact pharmacy education and practice across undergraduate, postgraduate, and professional levels.

🧪 Experience

Dr. Castelino has held progressive academic and clinical roles across India and Australia. He is currently Associate Professor at the University of Sydney (since 2023) and previously served as Senior Lecturer (2016–2022) and Lecturer at the University of Tasmania (2011–2016). His clinical experience includes roles as Renal Pharmacist at Blacktown Hospital (NSW, since 2016), Pharmacist at Calvary Health Care Tasmania (2012–2015), Clinical Educator at Royal Hobart Hospital, and Clinical Pharmacist in India (2004–2007). He has tutored at the University of Sydney (2008–2011) and coordinated various undergraduate and postgraduate subjects in pharmacy and nursing, including pharmacology, therapeutics, and evidence-based practice. Dr. Castelino has also served on scientific committees and has been instrumental in supervising PhD and MPhil candidates. His dual expertise in clinical pharmacy and academia supports a translational approach to patient care and education, positioning him as a bridge between hospital practice and academic advancement in medication safety and chronic disease management.

🏅 Awards and Honors

Dr. Ronald Castelino has received numerous accolades throughout his academic and professional career. He was awarded the Teaching Merit Certificate by the University of Tasmania in both 2013 and 2014 for excellence in education. His outstanding academic performance was recognized with the Second Rank in MPharm (Pharmacy Practice) by Rajiv Gandhi University of Health Sciences, Bangalore, India (2006). He was also the Gold Medallist and Best Outgoing Student at JSS College of Pharmacy, Mysore (2004–2005). In recognition of his expertise and leadership in nephrology and pharmacy research, he became a Fellow of the Australia and New Zealand College of Advanced Pharmacy (FANZCAP) in 2024. These awards underscore his commitment to advancing pharmacy practice, medical education, and health services research. His consistent recognition reflects both academic excellence and sustained contributions to pharmacy education, making him a highly respected educator and clinician in his field.

🔬 Research Focus

Dr. Castelino’s research centers on the quality use of medicines and chronic disease state management, particularly in kidney diseases. He leads a multidisciplinary research group at the University of Sydney dedicated to medication safety and health service improvement in nephrology. His translational research aligns with the University’s theme of “Better Health” and includes pharmacist-led medication review clinics, studies on metformin use in diabetes, and adverse drug reactions in elderly patients. He has supervised several PhD and MPhil students, with projects targeting medication regimen complexity in end-stage kidney disease and healthcare delivery models. Dr. Castelino’s work is informed by his clinical practice as a renal pharmacist and aims to bridge gaps between patient care and policy implementation. With over 97 publications, including book chapters and professional articles, his research has influenced both academic and hospital-based pharmacy practices. His focus remains on evidence-based interventions that enhance safety and outcomes in vulnerable populations.

Conclusion

Dr. Ronald Castelino exemplifies the integration of academic excellence, clinical expertise, and research leadership in pharmacy practice. Through his commitment to improving medication safety and chronic disease management, he bridges gaps between education, research, and patient care. His contributions continue to shape pharmacy education and nephrology research in Australia and beyond.

 

Publications

Elijah Stommel | Toxicology | Best Researcher Award

Dr. Elijah Stommel | Toxicology | Best Researcher Award

Dr. Elijah W. Stommel is a distinguished neurologist born in Hamilton, Bermuda 🌊, currently serving as Professor of Neurology at the Geisel School of Medicine at Dartmouth 🧠, renowned for his clinical expertise, pioneering ALS research, and dedication to patient-centered care 💡; his prolific academic journey, consulting roles, and leadership in rare disease research reflect decades of unwavering service to neurology 🏥, academia 📚, and public health advocacy 🧬.

Profile

Education 🎓

Dr. Stommel holds an M.D. (1987) and a Ph.D. in Physiology (1984) from Boston University School of Medicine 🎓; he earned a B.A. with High Honors in Music from Bowdoin College 🎵 (1977), pursued advanced coursework at MIT 🏛️, and honed his research skills as a Research Assistant at the Marine Biological Laboratory in Woods Hole 🔬 — blending physiology, neurology, and music to form a truly interdisciplinary academic foundation 📘.

Experience 👨‍🏫

With over three decades in clinical neurology 🧠, Dr. Stommel progressed from Chief Resident at Dartmouth-Hitchcock (1990-91) to Professor of Neurology (2013–present) 👨‍🏫; he has served as Staff Neurologist at Dartmouth-Hitchcock Clinic since 1991 🏥, held multiple consultant roles across Vermont and New Hampshire 🗺️, and co-directs the Electromyography Lab ⚡, establishing himself as a trusted educator, clinician, and research mentor in both academic and hospital environments 🌟.

Awards & Recognitions 🏅

Dr. Stommel’s commitment to humanism and excellence in neurology earned him a nomination for the prestigious Tow Humanism in Medicine Award 🏆 (2011); he is a Fellow of the American Academy of Neurology 🎖️ and holds long-standing certifications in Electrodiagnostic Medicine and Neurology 🧠, complemented by leadership roles on numerous committees advancing research ethics, clinical trials, and medical education 📋💡.

Research Interests 🔬

Dr. Stommel’s research revolves around neurodegenerative diseases, especially ALS 🧬, exploring environmental toxins 🌿, nanotechnology 🧪, and biomarkers 🔍 to advance diagnostics and therapeutics; as an active reviewer and editor for journals like Nature Nanotechnology, Frontiers in Neurology, and Molecular Neurobiology 🧠, he continually shapes scientific discourse while his collaborative work with global ALS consortia helps identify novel causal pathways and treatment avenues 🌍💡.

Publications